Yourgene Health (part of the Novacyt group of companies), a leading international molecular diagnostics group, today announced the launch of IONA® Care+, a fully comprehensive non-invasive prenatal ...

Rare diseases have become an attractive target for pharmaceutical companies both in Australia and internationally with ...

The council approved the £20 per hour fees for non-residential care, which include social supports, day opportunities and ...

Dr. Eric Levine’s cutting-edge autism research at UConn is reprogramming the donated skin or blood cells of Angelman or Dup15q syndrome patients to develop them in the lab into brain cells that ...

Dr. Eric Levine’s cutting-edge autism research at UConn School of Medicine is reprogramming the donated skin or blood cells ...

South San Francisco, CA, January 30, 2025 – The California Institute for Regenerative Medicine (CIRM), one of the world’s largest institutions dedicated to regenerative medicine, has awarded nearly ...

California Institute for Regenerative Medicine (CIRM) has awarded a $5.8 million translational research grant to a scientist at the University of California, Los Angeles (UCLA) to further support the ...

Several ASX-listed companies are undertaking phase III clinical trials, the critical final stage before potential regulatory ...

What is Zollinger-Ellison syndrome? Zollinger-Ellison syndrome (ZES) is a rare digestive disorder. If you have ZES, you likely have 1 or more tumors in the first part of the small intestine, the ...

Ultragenyx's pipeline is rich with promising candidates, with setrusumab for osteogenesis imperfecta (OI) and GTX-102 for Angelman syndrome leading the charge. Setrusumab, currently in Phase 3 ...